Plasma Fibroblast Growth Factor 23 Is Elevated in Pediatric Primary Hypertension

Yao Lin', Lin Shi*1, Yanyan Liu', Hongwei Zhang', Yang Liu', Xiaolan Huang2, Dongqing Hou3 and Mingming Zhang1

1 Department of Pediatric Cardiology, Children’s Hospital, Capital Institute of Pediatrics, Beijing, China, 2 Central Diagnostic Laboratory, Children’s Hospital, Capital Institute of Pediatrics, Beijing, China, 3 Department of Epidemiology, Children’s Hospital, Capital Institute of Pediatrics, Beijing, China

Fibroblast growth factor 23 (FGF 23), an endocrine hormone regulating the homeostasis of phosphate and vitamin D, has been shown to play a role in cardiovascular disease. Increased blood FGF 23 is found to be associated with elevated blood pressure in adults. However, measurement of FGF 23 in hypertensive children has not been documented. In this study, a total of 98 children with primary hypertension and 37 controls were recruited, and blood FGF 23 was comparatively investigated. Additionally, FGF 23 levels were compared between the subgroups of patients after hypertensive children were sub-grouped according to their cardiac geometry, hypertension stages, insulin levels, and weight. The case group had a FGF 23 level of 48.99 (16.42), expressed as the median (the interquartile range), significantly higher than the 41.72 (7.05) from the control group (p = 0.0002). While no remarkable differences were observed in FGF 23 levels between non-obese and obese hypertensive children, between patients with stage 1 and stage 2 hypertension, or between patients with normal and high insulin levels; hypertensive children with abnormal cardiac geometry had significantly higher levels of FGF 23 than patients with normal cardiac geometry (p = 0.0085). Our data revealed for the first time that hypertensive children have higher levels of FGF 23. Further studies are needed to examine if lowering FGF 23 improves the cardiac geometry in hypertensive children with higher FGF 23.

Keywords: FGF 23, pediatric primary hypertension, blood pressure, left ventricular hypertrophy, cardiovascular disease

INTRODUCTION

Fibroblast growth factor 23 (FGF 23), primarily produced by osteocytes and osteoblasts in bone, was originally recognized as an endocrine hormone by its canonical function to regulate the homeostasis of phosphate and vitamin D (1); it promotes urinary phosphate excretion, inhibits active vitamin D production and augments active vitamin D catabolism (1–4). Beyond serving as a phosphotrophic hormone, FGF 23 is a prognosis predictor of chronic kidney disease (CKD) (5–8). Studies exploring the role of FGF 23 in cardiovascular disease (CVD) have also established FGF 23 as a risk factor, independent of CKD, for CVD (9–16).

Pediatric primary hypertension is on the rise (17, 18). Children with high blood pressure (BP) are not only subject to organ damage such as left ventricular hypertrophy (LVH) (19), but also have a greater probability of developing adult hypertension, a major risk factor for CVD (20, 21). FGF 23
levels have been found to be positively associated with BP in adults (9, 22). However, blood FGF 23 levels in children with primary hypertension have not been documented. This study was designed to comparatively investigate blood FGF 23 levels in children with primary hypertension and those with normal blood pressure.

**METHODS**

**Ethics Approval and Consent**

This study was approved by the Medical Research Review Board of Children’s Hospital, Capital Institute of Pediatrics, Beijing, in accordance with the Declaration of Helsinki, the Code of Ethics of the World Medical Association. Written informed parental consent was obtained for all participants.

**Study Subjects and Blood Samples**

All subjects, aged 8–17 years, were recruited at our department. Children with primary hypertension formed the case group while those with normal blood pressure were included in the control group. Patients with secondary hypertension or conditions that affect kidneys or the cardiovascular, endocrine, or central nervous systems were excluded. All blood samples were obtained in the morning after overnight fasting. All blood pressure measurements were performed using the auscultation method as recommended by the Fourth Report on the Diagnosis, Evaluation, and Treatment of High Blood Pressure in Children and Adolescents, and the results were used for hypertension diagnosis and stage classification (23). Ambulatory BP monitoring was conducted for the computation of the mean BP during the day and night over a 24 h period using the DMS-ABP System (DM Software), which was used to rule out cases of white coat hypertension and obtain the mean systolic and diastolic pressures. Hypertension was diagnosed when the average systolic and/or diastolic BP was in the ≥95th percentile from the auscultation measurement on at least 3 separate occasions adjusted for gender, age and height. Stage 1 hypertension was diagnosed if a child’s BP was greater than the 95th percentile but less than or equal to the 99th percentile plus 5 mm Hg; and stage 2 hypertension was diagnosed if a child’s BP was greater than the 99th percentile plus 5 mm Hg (23).

**Echocardiography**

LVH was assessed by echocardiography. Left ventricular internal dimension (LVIDd), interventricular septal thickness (IVST) and left ventricular posterior wall thickness (LVPWT) at end-diastole were measured using the Philips iE33 Ultrasound System. Relative left ventricular wall thickness (RWT) was calculated as RWT=(IVST+LVPWT)/LVIDd; left ventricular mass (LVM) was calculated as LVM=1.04 × 0.8 × ((LVIDd+IVST+LVPWT)3−LVIDd3)+0.6 (24); and LVM index (LVMi) was calculated as LVMi=LVM/height2.7. We adopted the criteria proposed by Hietalampi et al. for the diagnosis of abnormal cardiac geometry (25), namely, LVMi ≥ 37.08 g/m2.7 in males, LVMi ≥ 34.02 g/m2.7 in females or RWT > 0.36 in either males or females is considered abnormal.

**Plasma FGF 23 Measurement**

Plasma FGF 23 levels were determined by an enzyme-linked immunosorbent assay using the Human FGF 23 (C-Term) ELISA Kit that measures the C-terminal fragment of FGF 23 (cFGF 23). The assay was performed and the FGF 23 level was expressed as the relative unit/ml (RU/ml) according to the manufacturer's instructions (Quidel Corporation, San Diego, USA).

**Fasting Insulin Measurement**

Fasting insulin was measured in the diagnostic laboratory of our hospital following a routine protocol.

**Statistical Analysis**

Data normality was determined by the Shapiro-Wilk test. Parametric continuous data were expressed as mean ± standard deviation (SD) and analyzed by two-tailed Student’s t-test. Non-parametric data were presented as median (the interquartile range) and analyzed by the Mann-Whitney test. p < 0.05 was considered statistically significant. All statistical analyses were performed using the SPSS 17.0 software (IBM Corporation, Armonk, USA).

**RESULTS**

**Demographics and the Blood Pressure of all Subjects**

A total of 98 hypertensive and 37 normotensive children, aged 8 to 17 years, were recruited. Demographics and blood pressures of all subjects are shown in **Table 1**. There is no substantial difference in average ages between the 2 groups. A previous report revealed that adolescents aged 12–15 years had higher levels of FGF 23 (26). In our series, the proportion of adolescents aged 12–15 years in the control group was 51.4% (19/37), similar to that in the case group (52.0%, 51/98). The case group had a significantly higher body mass index (BMI) than the control group. Both mean systolic and diastolic pressures in the case group were significantly higher than those in the control group (**Table 1**).

| TABLE 1 | Demographics and blood pressures of all subjects. |
|---------|---------------------------------------------|
| **Case group (n = 98)** | **Control group (n = 37)** |
| Age (years) | 11.8 ± 2.2 | 11.1 ± 2.2 |
| Number of males (%) | 78 (79.59) | 11 (29.73) |
| BMI (kg/m²) | 27.32 ± 5.26* | 18.01 ± 2.48 |
| Mean systolic pressure (mmHg) | 128.33 ± 12.39* | 117.73 ± 7.03 |
| Mean diastolic pressure (mmHg) | 72.89 ± 12.36** | 68.35 ± 5.58 |

Mean systolic pressure and mean diastolic pressure were obtained from the 24-hour ambulatory blood pressure measurement. Data are expressed as mean ± standard deviation; *p = 0.0001 and **p = 0.0024 compared with control group. BMI, body mass index.
Blood FGF 23 Levels Between Normotensive and Hypertensive Children

All FGF 23 levels were presented in the unit of RU/ml. The FGF 23 level in the case group was significantly higher than that of the control group (p = 0.0002, Table 2).

Blood FGF 23 Levels Between Subgroups of Patients

FGF 23 levels were compared between subgroups of patients. As shown in Table 3, there were no significant differences in FGF 23 levels between non-obese and obese hypertensive children, between patients with stage 1 and stage 2 hypertension, or between patients with normal and high insulin levels (Table 3). However, hypertensive children with abnormal cardiac geometry had significantly higher levels of FGF 23 than patients with normal cardiac geometry (Table 3).

DISCUSSION

In the present study, we comparatively investigated blood FGF 23 levels in hypertensive and normotensive children, and reported that (1) children with primary hypertension had significantly higher levels of FGF 23 than controls; (2) FGF 23 levels in patients with abnormal cardiac geometry were markedly higher than those in patients with normal cardiac geometry; and (3) there were no significant differences in FGF 23 levels between non-obese and obese hypertensive children, between patients with stage 1 and stage 2 hypertension, or between patients with normal and high insulin levels. Previous studies have shown that FGF 23 levels do not differ between genders (26–28), which was also observed in our study (data not shown).

### TABLE 2 | Comparison of FGF 23 levels (RU/ml) between the case and control groups.

| Subgroup | Case group (n = 98) | Control group (n = 37) | p-value |
|----------|---------------------|------------------------|---------|
| FGF levels | 48.99 (16.42) | 41.72 (7.05) | 0.00002 |

FGF levels were presented as median (the interquartile range). P value was determined by the Mann-Whitney test.

### TABLE 3 | Comparison of FGF 23 levels (RU/ml) between subgroups of patients.

| Subgroup | Case group (n = 98) | Control group (n = 37) | p-value |
|----------|---------------------|------------------------|---------|
| Non-obese (n = 35) | 49.05 (19.08) | 48.92 (14.75) | 0.52 |
| Obese (n = 63) | 48.52 (17.44) | 51.36 (19.68) | 0.28 |
| Stage 1 (n = 68) | 48.52 (17.44) | 51.36 (19.68) | 0.28 |
| Stage 2 (n = 30) | 48.52 (17.44) | 51.36 (19.68) | 0.28 |
| Normal insulin (n = 56) | 49.36 (17.68) | 53.66 (22.97) | 0.44 |
| High insulin (n = 17) | 49.36 (17.68) | 53.66 (22.97) | 0.44 |
| Normal cardiac geometry | 48.08 (17.48) | 55.01 (20.18) | 0.00001 |
| Abnormal cardiac geometry | 48.08 (17.48) | 55.01 (20.18) | 0.00001 |

Data are presented as median (the interquartile range). P value was determined by the Mann-Whitney test.

FGF 23 is a protein consisting of 251 amino acids with an N-terminal region that contains the conserved FGF homology domain and a C-terminus of 71-amino acid (3). There are 2 forms of FGF 23 identified in circulation: one is the intact FGF 23 and the other is the C-terminal fragment of FGF-23 that is created by proteolysis (29). It has been shown that cFGF-23 is biologically active, e.g., it retains phosphaturic activity (29). The cFGF23 ELISA kit detects both intact FGF 23 and cFGF 23 and is preferentially used in the measurement of blood FGF 23 (26). In view of these facts, we chose the cFGF23 ELISA kit for this study. FGF 23 levels are independent of gender in the pediatric population (26–28). Therefore, the cases and controls were matched only by age in this study.

As one of the most important regulators of blood phosphate, FGF 23 stimulates urinary phosphate excretion. It has been shown in both adult and pediatric patients that FGF 23 levels rise as kidney function declines (5–8, 25, 27, 28, 30). As a marker of CVD, circulating FGF 23 is found positively related to blood pressure in adults (9, 22). In a case-control study, Gutiérrez et al. found that adults with hypertension had significantly higher FGF 23 than those without hypertension (9). In a prospective observational study exploring the associations of FGF 23 levels with longitudinal BP changes and incident hypertension in young and middle-aged adults, Akhabue et al. revealed that at the 5 and 10-year-follow-up visits the subjects in the highest FGF 23 quartile had a greater chance to develop hypertension than those in the lowest FGF 23 quartile, indicating that higher FGF 23 levels increase the risk of incident hypertension (22).

In the present study, we observed increased plasma FGF 23 levels in pediatric patients with primary hypertension. To date, circulating FGF 23 measurement in hypertensive children has not been documented. Zajac et al. discovered that hypertensive children and adolescents had significantly higher urine FGF 23 levels than controls, but they did not measure blood FGF 23 (31). We speculate that higher urine FGF 23 concentrations in hypertensive participants might be a result of increased blood FGF 23 levels.

FGF 23 has been shown to be independently associated with left ventricular mass, hypertrophy and geometry in adult patients with or without CKD (13–15, 32). Additionally, in animal studies direct hypertrophic effects of FGF 23 on isolated neonatal rat ventricular cardiomyocytes is observed (13). It has also been demonstrated that direct injection of FGF 23 protein into the left ventricular myocardium of mice results in LVH (13). These findings support a causal role of FGF 23 in LVH. In contrast, Agarwal et al. revealed that FGF 23 was not associated with LVH in patients with coronary artery disease (33). We reported here that children with abnormal cardiac geometry had remarkably higher blood FGF 23 levels than those with normal cardiac geometry. This finding is in agreement with the data presented in a study showing that FGF 23 values were significantly higher in adolescents with eccentric or concentric LVH compared with those without hypertrophy (34). The increase of FGF 23 found in our study is unlikely a result of kidney disease as all participants had normal kidney function. Further studies to examine if lowering
FGF 23 improves cardiac geometry in those with higher FGF 23 will help uncover if FGF 23 plays a determinant role in LVH in children.

Hypertensive children have a higher rate of obesity (23, 35, 36), which is also seen in this study. Elevated FGF 23 levels have been documented in obese vs. non-obese adults and adolescents as well (34, 37). Ali et al. found that obese adolescents or adolescents with higher fasting insulin concentrations had elevated FGF 23 in a study population consisting exclusively of African Americans (34). In contrast, our results showed that there were no significant differences in FGF 23 levels between obese and non-obese hypertensive children, or between patients with normal and high insulin levels. These discrepancies might be due to racial differences.

Considering that this is a small-scale study from a single center, the generalizability of our data might be limited. Additionally, the control group is about a third the size of the cases, which might limit the statistical power. Further studies in a large series and in other race and ethnic groups are needed.

AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

FUNDING

This study was supported by the Capital Institute of Pediatric Incubating Program (grant No: PY-2017-11), the Beijing Municipal Administration of Hospitals Incubating Program (grant No: PX2018076) and the Special Fund of the Pediatric Medical Coordinated Development Center of Beijing Municipal Administration (grant No: XTYB201801).

REFERENCES

1. Shimada T, Kakitani M, Yamasaki Y, Hasegawa H, Takeuchi Y, Fujita T, et al. Targeted ablation of FGF 23 demonstrates an essential physiological role of FGF 23 in phosphate and vitamin D metabolism. J Clin Invest. (2004) 113:561–8. doi: 10.1172/JCI200419081
2. Erben RG. Pleiotropic actions of FGF 23. Toxicol Pathol. (2017) 45:904–10. doi: 10.1177/0192623317737469
3. Liu S, Quares L D. How fibroblast growth factor 23 works. J Am Soc Nephrol. (2007) 18:1637–47. doi: 10.1681/ASN.2007010068
4. Bowe AE, Finnegan R, Jan de Beur SM, Cho J, Levine MA, Kumar R, et al. FGF-23 inhibits renal tubular phosphate transport and is a phex substrate. Biochem Biophys Res Commun. (2001) 284:977–81. doi: 10.1006/bbrc.2001.5084
5. Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. (2011) 305:2432–9. doi: 10.1001/jama.2011.826
6. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, et al. Targeted ablation of FGF 23 demonstrates an essential physiological role of FGF 23 in phosphate and vitamin D metabolism. J Clin Invest. (2004) 113:561–8. doi: 10.1172/JCI200419081
7. Jean G, Terrat JC, VANEL T, Hurot JM, Lorraiaux C, Mayor B, et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. (2009) 24:2792–6. doi: 10.1093/ndt/gfp191
8. Greenhill C. Risk factors: levels of FGF23 predict outcomes in advanced CKD. Nat Rev Nephrol. (2011) 7:606. doi: 10.1038/nrneph.2011.130
9. Gutierrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol. (2011) 6:2871–8. doi: 10.2215/CJN.02740311
10. Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C, et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the Multi-Ethnic Study of Atherosclerosis. Circ Heart Fail. (2014) 7:409–6. doi: 10.1161/CIRCHEARTFAILURE.113.000952
11. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating fibroblast growth factor-23 is associated with vascular dysfunction in the community. Atherosclerosis. (2009) 205:385–90. doi: 10.1016/j.atherosclerosis.2009.01.001
12. Udell JA, Morrow DA, Jarolim P, Sloan S, Hoffman EB, O’Donnell TF, et al. Fibroblast growth factor-23, cardiovascular prognosis, and benefit of angiotensin-converting enzyme inhibition in stable ischemic heart disease. J Am Coll Cardiol. (2014) 63:2421–8. doi: 10.1016/j.jacc.2014.03.026
13. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF 23 induces left ventricular hypertrophy. J Clin Invest. (2011) 121:4393–408. doi: 10.1172/JCI46122
14. Kirkpantur A, Balci M, Gurbuz OA, Afsar B, Cambakan R, Aldemir R, et al. Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant. (2011) 26:1346–54. doi: 10.1093/ndt/gfg539
15. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF 23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. (2009) 207:546–51. doi: 10.1016/j.atherosclerosis.2009.05.013
16. Stevens KK, McQuarrie EP, Sands W, Hillyard DZ, Patel RK, Mark PB, et al. Fibroblast growth factor 23 predicts left ventricular mass and induces cell adhesion molecule formation. Int J Nephrol. (2011) 2011:297070. doi: 10.4061/2011/297070
17. Din-Dzietham R, Liu Y, Bielo VM, Shamsa F. High blood pressure trends in children and adolescents in national surveys, 1963 to 2002. Circulation. (2007) 116:1488–96. doi: 10.1161/CIRCULATIONAHA.106.683243
18. Roulet C, Bovet P, Brauchli T, Simeoni U, Xi B, Santschi V, et al. Secular trends in blood pressure in children: a systematic review. J Clin Hypertens. (2017) 19:488–97. doi: 10.1111/jch.12955
19. Ritchey PA, Disessa TG, Somes GW, Alpert BS, Jones DP. Left ventricular geometry in children and adolescents with primary hypertension. Am J Hypertens. (2010) 23:234–9. doi: 10.1038/ajh.2009.164
20. McCrindle BW, Manlihot C, Millar K, Gibson D, Stearnie K, Kilty H, et al. Population trends toward increasing cardiovascular risk factors in Canadian adolescents. J Pediatr. (2010) 157:837–43. doi: 10.1016/j.jpeds.2010.05.014
21. Chen X, Wang Y. Tracking of blood pressure from childhood to adulthood: a systematic review and meta-regression analysis. Circulation. (2008) 117:3171–80. doi: 10.1161/CIRCULATIONAHA.107.730366
22. Akabue E, Montag S, Reis JP, Pool LR, Mehta R, Yancy CW, et al. FGF 23 (Fibroblast Growth Factor-23) and incident hypertension in young and middle-aged adults: the CARDIA Study. Hypertension. (2018) 72:70–6. doi: 10.1161/HYPERTENSIONAHA.118.11066
23. National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents. The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics. (2004) 114:555–76. doi: 10.1542/peds.114.2.S2.555
24. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. (1986) 57:450–8. doi: 10.1016/0002-9149(86)00771-X
25. Hietalampi H, Pahkala K, Jokinen E, Rönnemaa T, Vuikari JS, Numikoski H, et al. Left ventricular mass and geometry in adolescence: early childhood determinants. (2012) 60:1266–72. doi: 10.1161/HYPERTENSIONAHA.112.194290
26. Fischer DC, Mischek A, Wolf S, Rahm A, Salweski B, Kundt G, et al. Paediatric reference values for the C-terminal fragment of fibroblast-growth factor-23, sclerostin, bone-specific alkaline phosphatase and isoform 5b of tartrate-resistant acid phosphatase. *Ann Clin Biochem*. (2012) 49:546–53. doi: 10.1258/acb.2012.011274

27. Sinha MD, Turner C, Dalton RN, Rasmussen P, Waller S, Booth CJ, et al. Investigating FGF-23 concentrations and its relationship with declining renal function in paediatric patients with pre-dialysis CKD Stages 3–5. *Nephrol Dial Transplant*. (2012) 27:4361–8. doi: 10.1093/ndt/gfs109

28. Bacchetta J, Dubourg L, Harambat J, Ranchin B, Abou-Jaoude P, Arnaud S, et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. *J Clin Endocrinol Metab*. (2010) 95:1741–8. doi: 10.1210/jc.2009-1576

29. Berndt TJ, Craig TA, McCormick DJ, Lanske B, Sitara D, Razzaque MS, et al. Biological activity of FGF-23 fragments. *Pflugers Arch*. (2007) 454:615–23. doi: 10.1007/s00424-007-0231-5

30. van Hussen M, Fischer AK, Lehnhardt A, Klaassen I, Möller K, Müller-Wiefel DE et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. *Kidney Int*. (2010) 78:200–6. doi: 10.1038/ki.2010.107

31. Zajač M, Rybi-Szmurlińska A, Wasilewska A. Urine fibroblast growth factor 23 levels in hypertensive children and adolescents. *Croat Med J*. (2015) 56:344–50. doi: 10.3325/cmj.2015.56.344

32. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. *Circulation*. (2009) 119:2545–52. doi: 10.1161/CIRCULATIONAHA.108.844506

33. Agarwal I, Ide N, Ikeda H, Kestenbaum B, Lanske B, Schiller NB, et al. Fibroblast growth factor-23 and cardiac structure and function. *J Am Heart Assoc*. (2014) 3:e000584. doi: 10.1161/JAHA.113.000584

34. Ali FN, Falkner B, Gidding SS, Price HE, Keith SW, Langman CB. Fibroblast growth factor-23 in obese, normotensive adolescents is associated with adverse cardiac structure. *J Pediatr*. (2014) 165:738–43. doi: 10.1016/j.jpeds.2014.06.027

35. Sorof J, Daniels S. Obesity hypertension in children: a problem of epidemic proportions. *Hypertension*. (2002) 40:441–7. doi: 10.1161/01.HYP.0000032940.33466.12

36. Brady TM. Obesity-related hypertension in children. *Front Pediatr*. (2017) 5:197. doi: 10.3389/fped.2017.00197

37. Grethen E, Hill KM, Jones R, Cacucci BM, Gupta CE, Acton A, et al. Serum leptin, parathyroid hormone, 1,25-dihydroxyvitamin D, fibroblast growth factor 23, bone alkaline phosphatase, and sclerostin relationships in obesity. *J Clin Endocrinol Metab*. (2012) 97:1655–62. doi: 10.1210/jc.2011-2280

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Lin et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.